Juch Herbert, Lupattelli Angela, Ystrom Eivind, Verheyen Sarah, Nordeng Hedvig
Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria; Institute of Human Genetics, Medical University of Graz, Graz, Austria.
PharmacoEpidemiology and Drug Safety Research Group, School of Pharmacy, PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
Patient Educ Couns. 2016 Oct;99(10):1699-707. doi: 10.1016/j.pec.2016.04.006. Epub 2016 Apr 11.
To evaluate patterns of and factors associated with a lack of pharmacotherapy as well as low adherence to treatment of hypothyroidism in pregnancy.
This multinational, cross-sectional, internet-based study recruited pregnant woman in 18 countries. Data about women's socio-demographic and medical characteristics, medication adherence (8-item Morisky Medication Adherence Scale), beliefs about medication (Beliefs about Medicine Questionnaire), and personality traits (Big Five Personality Trait questionnaire) were collected via an online questionnaire.
229 of 5095 women had hypothyroidism during pregnancy; of these, 93% reported hypothyroidism pharmacotherapy. Adherence was low among 17% (95% CI: 12.5-22.5%) of medicated women, whilst it was moderate and high among 44% and 39%, respectively. Not using folic acid and not living in a stable relationship were associated with an increased likelihood for untreated hypothyroidism. Younger maternal age and not using folic acid in pregnancy were factors significantly associated with low adherence. Conscientiousness and the perception that the benefit of pharmacotherapy outweighed the risks were associated with higher levels of adherence.
There is room for improvement of adherence to hypothyroidism treatment in pregnancy.
Counselling of women with hypothyroidism in pregnancy should include a proper risk communication and information framing, to ameliorate maternal and foetal health.
评估妊娠期甲状腺功能减退症药物治疗缺失及治疗依从性低的模式和相关因素。
这项基于互联网的跨国横断面研究招募了18个国家的孕妇。通过在线问卷收集了有关女性社会人口统计学和医学特征、药物治疗依从性(8项Morisky药物治疗依从性量表)、对药物的信念(药物信念问卷)以及人格特质(大五人格特质问卷)的数据。
5095名女性中有229名在孕期患有甲状腺功能减退症;其中,93%报告接受了甲状腺功能减退症药物治疗。在接受药物治疗的女性中,17%(95%置信区间:12.5 - 22.5%)的依从性较低,而分别有44%和39%的女性依从性为中等和较高。未使用叶酸以及未处于稳定关系与未经治疗的甲状腺功能减退症可能性增加相关。母亲年龄较小以及孕期未使用叶酸是与低依从性显著相关的因素。尽责性以及认为药物治疗的益处大于风险与较高的依从性水平相关。
妊娠期甲状腺功能减退症治疗的依从性有改善空间。
对妊娠期甲状腺功能减退症女性的咨询应包括适当的风险沟通和信息构建,以改善母婴健康。